Tulsa-based Schusterman Interests, the family office behind billionaire investors Charles and Lynn Schusterman, has made a substantial investment in HeartFlow, Inc., an artificial intelligence-driven healthcare technology company specialising in heart diagnostics. According to a November 14 filing with the U.S. Securities and Exchange Commission, Schusterman Interests acquired over 1.9 million shares of HeartFlow during the third quarter, valued at approximately $65.3 million as of September 30, making it the fourth-largest position in their portfolio. This purchase represents 14.9% of the fund’s reported assets under management, highlighting significant confidence in HeartFlow’s potential growth trajectory.

HeartFlow, which went public in early August 2025, has seen a remarkable stock performance since its initial public offering (IPO). Shares were priced at $19 during the upsized IPO but have climbed roughly 70% to $32.25 as of late November, reflecting robust investor demand. The company’s IPO raised roughly $316.7 million, selling 16.7 million shares initially at $19 each, and subsequently extended through an underwriters' option resulting in total gross proceeds of around $364.2 million. HeartFlow’s shares started trading on the Nasdaq Global Select Market under the ticker symbol ‘HTFL’ on August 8, 2025.

HeartFlow’s core proposition lies in its proprietary AI-powered platform that aids non-invasive diagnosis and management of coronary artery disease. The company leverages computational fluid dynamics and imaging analytics to provide enhanced clinical insights to healthcare providers, offering the potential to improve patient outcomes through precision diagnostics. While the company generated revenue of $161.9 million over the trailing twelve months, it continues to operate at a net loss, with recent figures showing a net loss of $125.4 million, consistent with the challenges many early-stage medtech firms face in scaling technology within a traditionally under-digitised healthcare sector.

The Schusterman family's investment signals growing institutional interest in HeartFlow despite those losses. Their confidence aligns with the increasing focus on AI-driven innovations in medical technology, particularly those that can deliver actionable clinical insights and improve healthcare efficiency. HeartFlow's combination of AI, cardiology, and data-driven diagnostic tools places it at a strategic intersection attractive to long-term investors who see potential for durable revenue growth as the platform expands globally.

Alongside HeartFlow, Schusterman Interests holds sizeable positions in other assets, with the largest being Karman at $148 million (33.8% of its portfolio), followed by RSP ($118.6 million) and SPY ($88.3 million), indicating a diversified yet selectively concentrated investment approach. Market watchers will be closely observing whether HeartFlow’s early momentum in stock performance and technological promise will translate into sustained commercial success in a competitive medtech landscape.

HeartFlow’s market debut and subsequent attention by prominent investors illustrate a broader trend in healthcare investment, where artificial intelligence and precision diagnostics are becoming central to cutting-edge medical solutions. Nonetheless, potential investors should remain mindful that the company is still in an early operational phase, balancing revenue growth with significant research and development expenses and market expansion efforts.

📌 Reference Map:

  • [1] (Fool.com) - Paragraph 1, Paragraph 3, Paragraph 4, Paragraph 5, Paragraph 6, Paragraph 7
  • [2] (Fool.com) - Paragraph 1, Paragraph 2
  • [3] (HeartFlow.com) - Paragraph 2
  • [4] (Investing.com) - Paragraph 2
  • [5] (Investing.com) - Paragraph 2
  • [6] (Reuters) - Paragraph 3
  • [7] (Reuters) - Paragraph 2

Source: Noah Wire Services